Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [1] Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
    Mazieres, Julien
    Zalcman, Gerard
    Crino, Lucio
    Biondani, Pamela
    Barlesi, Fabrice
    Filleron, Thomas
    Dingemans, Anne-Marie C.
    Lena, Herve
    Monnet, Isabelle
    Rothschild, Sacha I.
    Cappuzzo, Federico
    Besse, Benjamin
    Thiberville, Luc
    Rouviere, Damien
    Dziadziuszko, Rafal
    Smit, Egbert F.
    Wolf, Jurgen
    Spirig, Christian
    Pecuchet, Nicolas
    Leenders, Frauke
    Heuckmann, Johannes M.
    Diebold, Joachim
    Milia, Julie D.
    Thomas, Roman K.
    Gautschi, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 992 - +
  • [2] Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures
    Deng, Huiyan
    Liu, Chang
    Zhang, Guoliang
    Wang, Xiaoling
    Liu, Yueping
    PATHOLOGY RESEARCH AND PRACTICE, 2018, 214 (12) : 2103 - 2105
  • [3] NCOA1-ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
    Cao, Qi
    Liu, Zhiguang
    Huang, Yanhua
    Qi, Chuang
    Yin, Xiaowei
    ONCOTARGETS AND THERAPY, 2019, 12 : 1071 - 1074
  • [4] TP53 Mutations Predict for Poor Survival in ALK Rearrangement Lung Adenocarcinoma Patients Treated with Crizotinib
    Wang, W.
    Xu, C.
    Chen, Y.
    Zhuang, W.
    Lin, G.
    Chen, X.
    Wu, B.
    Huang, Y.
    Chen, R.
    Guan, Y.
    Yi, X.
    Fang, M.
    Lv, T.
    Chen, G.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
  • [5] High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma
    Xu, Yuyin
    Chang, Heng
    Wu, Lijing
    Zhang, Xin
    Zhang, Ling
    Zhang, Jing
    Li, Yuan
    Shen, Lei
    Zhu, Xiaoli
    Zhou, Xiaoyan
    Bai, Qianming
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 117
  • [6] A lung squamous carcinoma patient with ROS1 rearrangement sensitive to crizotinib
    Ju, Lixia
    Han, Mingquan
    Su, Jinmei
    Wu, Chunyan
    Dong, Zhengwei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) : 561 - 564
  • [7] Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib
    Chen, Yao
    Zhang, Xiaochen
    Jiang, Qi
    Wang, Bo
    Wang, Yina
    Yan Junrong
    LUNG CANCER, 2020, 146 : 370 - 372
  • [8] ALK and ROS 1 concurrent with EGFR mutation in patients with lung adenocarcinoma
    Mao, Yanjiao
    Wu, Shixiu
    ONCOTARGETS AND THERAPY, 2017, 10 : 3399 - 3404
  • [9] Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report
    Kinoshita, Ryosuke
    Nakao, Makoto
    Kiyotoshi, Hiroko
    Hayashi, Syuntaro
    Sugihara, Masahiro
    Hirata, Yuya
    Kuriyama, Mamiko
    Takeda, Norihisa
    Muramatsu, Hideki
    ONCOLOGY LETTERS, 2023, 26 (06)
  • [10] Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer
    Clark, Jeffrey W.
    Camidge, D. Ross
    Kwak, Eunice L.
    Maki, Robert G.
    Shapiro, Geoffrey I.
    Chen, Isan
    Tan, Weiwei
    Randolph, Sophia
    Christensen, James G.
    Ozeck, Mark
    Tang, Yiyun
    Wilner, Keith D.
    Salgia, Ravi
    FUTURE ONCOLOGY, 2020, 16 (01) : 4289 - 4301
12345